Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $35.89

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has received an average rating of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $35.78.

SNDX has been the topic of several research reports. Stifel Nicolaus boosted their price objective on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday. JPMorgan Chase & Co. cut their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Jefferies Financial Group initiated coverage on Syndax Pharmaceuticals in a report on Friday, June 28th. They set a “buy” rating and a $37.00 price objective for the company. HC Wainwright lifted their target price on Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Finally, Bank of America upped their price target on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th.

Syndax Pharmaceuticals Trading Up 0.7 %

SNDX stock opened at $19.89 on Monday. Syndax Pharmaceuticals has a 1-year low of $11.22 and a 1-year high of $25.34. The business’s 50-day moving average price is $19.34 and its two-hundred day moving average price is $20.62. The firm has a market cap of $1.69 billion, a PE ratio of -6.18 and a beta of 0.91.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Thursday, August 1st. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.11. The company had revenue of $3.50 million for the quarter. The business’s revenue for the quarter was up 3499999990.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.64) EPS. On average, analysts forecast that Syndax Pharmaceuticals will post -3.66 earnings per share for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several large investors have recently made changes to their positions in SNDX. Northwestern Mutual Wealth Management Co. acquired a new position in Syndax Pharmaceuticals during the second quarter worth $27,000. nVerses Capital LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at about $33,000. Quarry LP lifted its stake in Syndax Pharmaceuticals by 75.0% in the 2nd quarter. Quarry LP now owns 6,125 shares of the company’s stock valued at $126,000 after purchasing an additional 2,625 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in Syndax Pharmaceuticals by 28.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock valued at $171,000 after purchasing an additional 1,587 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in Syndax Pharmaceuticals by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after purchasing an additional 1,312 shares during the period.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).